Israel-based Teva Pharmaceutical Industries Ltd (NYSE and TASE: TEVA) has launched a generic version of VESIcare (solifenacin succinate) Tablets, 5mg and 10mg, in the United States, it was reported yesterday.
The products are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin Succinate Tablets are contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug.
VESIcare Tablets have annual sales of more than USD955m in the US, according to IQVIA data as of February 2019.
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg
Dr. Reddy's Laboratories Launches Testosterone Gel, 1.62% in the US Market
Teva Provides Update on Fremanezumab Clinical Development for Use in Episodic Cluster Headache
Teva Launches Generic Version of VESIcare Tablets in the United States
Teva Pharmaceutical begins US launch of generic VESIcare tablets
Oakrum Pharma signs product development and commercialisation partnership with Biophore
Teva Pharmaceutical launches generic version of VESIcare tablets in the US
Phyton Biotech and AqVida receive European approval for paclitaxel injectable FDF
The United States Food and Drug Administration approves Narcan
Teva Signs New USD 2.3bn Syndicated Revolving Credit Facility
Endo announces delivery of authorised generic PROVENTIL (albuterol sulfate) in the US